Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.38
+0.01 (0.07%)
At close: Mar 19, 2026, 4:00 PM EDT
14.35
-0.03 (-0.21%)
Pre-market: Mar 20, 2026, 6:13 AM EDT
Amicus Therapeutics Market Cap
Amicus Therapeutics has a market cap or net worth of $4.52 billion as of March 20, 2026. Its market cap has increased by 65.15% in one year.
Market Cap
4.52B
Enterprise Value
4.66B
1-Year Change
65.15%
Ranking
Category
Stock Price
$14.38
Market Cap Chart
Since May 31, 2007, Amicus Therapeutics's market cap has increased from $320.80M to $4.52B, an increase of 1,307.52%. That is a compound annual growth rate of 15.09%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 18, 2026 | 4.51B | 2.70% |
| Dec 31, 2025 | 4.39B | 56.09% |
| Dec 31, 2024 | 2.81B | -32.36% |
| Dec 29, 2023 | 4.16B | 21.31% |
| Dec 30, 2022 | 3.43B | 6.59% |
| Dec 31, 2021 | 3.22B | -46.51% |
| Dec 31, 2020 | 6.02B | 142.45% |
| Dec 31, 2019 | 2.48B | 36.86% |
| Dec 31, 2018 | 1.81B | -24.21% |
| Dec 29, 2017 | 2.39B | 238.22% |
| Dec 30, 2016 | 707.40M | -41.61% |
| Dec 31, 2015 | 1.21B | 83.56% |
| Dec 31, 2014 | 660.00M | 466.04% |
| Dec 31, 2013 | 116.60M | -12.00% |
| Dec 31, 2012 | 132.50M | 11.16% |
| Dec 30, 2011 | 119.20M | -8.24% |
| Dec 31, 2010 | 129.90M | 44.49% |
| Dec 31, 2009 | 89.90M | -50.11% |
| Dec 31, 2008 | 180.20M | -25.01% |
| Dec 31, 2007 | 240.30M | -25.09% |
| May 31, 2007 | 320.80M | - |
View and export this data all the way back to 2007. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caris Life Sciences | 5.22B |
| Celcuity | 5.21B |
| Immunovant | 4.80B |
| TG Therapeutics | 4.80B |
| Apogee Therapeutics | 4.64B |
| CRISPR Therapeutics AG | 4.58B |
| Scholar Rock Holding | 4.57B |
| Terns Pharmaceuticals | 4.30B |